Data Foundry

Medical device recalls 2016

The THERAKOS CELLEX Photopheresis System is a photoimmune therapy — Class II medical device recall Z-1322-2016

Terminated recall by Therakos Inc, reported 2016-04-13, distributed nationwide. The Mallinckrodt (Therakos) post-market monitoring process detected an increased trend in tubing leaks within

Recall numberZ-1322-2016
Product typeMedical device
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmTherakos Inc, West Chester, PA, United States
Recall initiated2015-12-21
Classified2016-04-05
Reported by FDA2016-04-13
Terminated2016-10-14
DistributedNationwide (US)
Quantity729 units
Reason classespackaging
UPC / GTIN / UDI-DI20705030200003
Lot numbersD342

Product

The THERAKOS CELLEX Photopheresis System is a photoimmune therapy. Catalog CLXUSA. Manufacturing lot D342 UDI: 20705030200003 The system designed to separate the patient's blood into various fractions and collect the white blood cell (WBC) fraction. The WBC fraction is treated with a photoactive drug UVADEX¿ (methoxsalen) Sterile Solution. The UVADEX is photo-activated by UVA light and results in the WBCs undergoing apoptosis

Reason for recall

The Mallinckrodt (Therakos) post-market monitoring process detected an increased trend in tubing leaks within the pump tubing organizer, associated with a portion of Kits from Lot D 342.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-1322-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.